On December 6, 2020 Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, reported that data on a novel assay for selection of acute myeloid leukemia (AML) patients for treatment with AMV564, at the 62nd Annual American Society of Hematology (ASH) (Free ASH Whitepaper) Meeting and Exposition (ASH 2020), taking place virtually from December 5-8, 2020 (Press release, Amphivena Therapeutics, DEC 6, 2020, View Source [SID1234572261]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AMV564 is the lead candidate from the AMPHIVENA ReSTORETM (Relieve Suppression of T cells in Oncology and Reinvigorate Effectors) platform of bivalent T-cell engagers, and has been studied in 2 Ph1 clinical studies in relapsed/refractory AML (NCT03144245) and in patients with advanced solid tumor malignancies (NCT04128423). AMV564 selectively depletes both myeloid derived suppressor cells (MDSC) and leukemic blasts via avid binding to clustered CD33, has been well tolerated with no dose-limiting toxicities reported and has shown single-agent activity across both R/R AML and solid tumors.
This novel assay could identify patients most likely to experience deeper and more durable responses with AMV564 therapy
The assay leverages the selectivity of AMV564 in a screening format to identify AML patients in whom leukemic blasts are expressing CD33 in a predominantly clustered configuration. "While AMV564 has demonstrated early signs of efficacy and anti-leukemic blast activity across an unselected relapsed/refractory AML population, this novel assay could identify patients most likely to experience deeper and more durable responses with AMV564 monotherapy", said Curtis Ruegg, Ph.D., President and CEO of Amphivena.
Details of the Presentation:
Title:
Selectivity of T Cell Engager AMV564 Against Different Leukemic Blast Populations and Potential Application for Patient Selection
Authors:
Sarde, A. et al.
Abstract Number:
1976
Session:
Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Poster Viewing:
Sunday, December 6, 2020: 7:00 AM-3:30 PM EST
The abstract and presentation are available on the ASH (Free ASH Whitepaper) Annual Meeting, and Amphivena websites.
About AMV564
AMV564 relieves immune suppression via targeted depletion of immunosuppressive myeloid derived suppressor cells (MDSC) and drives T cell activation and polarization to restore anti-cancer immunity. To date, over 95 patients have received AMV564 across three Phase 1 clinical trials for patients with solid tumors, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS).